Literature DB >> 20160493

Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours.

Anthony R Mato1, Selina M Luger, Daniel F Heitjan, Mark E Mikkelsen, Erin Olson, Chaitra Ujjani, Samantha Jacobs, Andrea N Miltiades, Payal Shah, Stephen J Schuster, Martin Carroll, Ann Duskin Chauffe, Barry D Fuchs.   

Abstract

BACKGROUND: Hospitalized patients who develop febrile neutropenia (FN) are treated empirically with antibiotics due to a high risk of developing septic shock. Currently, there is no method to predict which patients are at greatest risk. This study was designed to determine whether serum lactate, measured at the time of FN, is associated with the development of septic shock in hospitalized hematologic malignancy (HM) patients.
RESULTS: Of the 547 patients enrolled, 46 (8.4%; 95% CI 6.2-10.9) developed septic shock. Baseline characteristics were similar between the groups. In univariate analysis, tachypnea (OR 5.9; 95% CI: 2.0-16.9, p = 0.001) and lactate (OR 18.4; 95% CI: 4.1-81.6, p < 0.001) were significantly associated with the development of septic shock. In multivariate analysis, lactate and tachypnea remained independently associated with the development of septic shock. By ROC analysis, lactate provided incremental prognostic value compared to vital signs alone.
METHODS: Vital signs and lactate were measured during episodes of FN. The primary endpoint was the development of septic shock. Using a prospective, nested, case-control design, controls were matched on length of stay at the time of septic shock to achieve 80% power to detect an OR of >or=2.5. Using logistic regression, we evaluated the association of vital signs and lactate with the subsequent development of septic shock.
CONCLUSIONS: In FN patients, measurement of lactate during FN adds significant prognostic information about the risk of developing septic shock. Routine measurement of lactate may help identify patients who may benefit from increased monitoring and early intervention strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160493     DOI: 10.4161/cbt.9.8.11270

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Implementation of modified early-goal directed therapy for sepsis in the emergency center of a comprehensive cancer center.

Authors:  Katy M Hanzelka; Sai-Ching J Yeung; Gary Chisholm; Kelly Willis Merriman; Susan Gaeta; Imrana Malik; Terry W Rice
Journal:  Support Care Cancer       Date:  2012-09-07       Impact factor: 3.603

Review 2.  The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.

Authors:  Jean Klastersky; Marianne Paesmans
Journal:  Support Care Cancer       Date:  2013-02-27       Impact factor: 3.603

3.  Serum Lactate: A Predictor of Septic Shock in Childhood Cancers with Febrile Neutropenia.

Authors:  Detchvijitr Suwanpakdee; Warakorn Prasertsin; Chanchai Traivaree; Piya Rujkijyanont
Journal:  Glob Pediatr Health       Date:  2021-05-31

4.  Outcome of severe infections in afebrile neutropenic cancer patients.

Authors:  Ksenija Strojnik; Ksenija Mahkovic-Hergouth; Barbara Jezersek Novakovic; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2016-02-10       Impact factor: 2.991

5.  Plasma lactate measurement as an example of encountered gaps between routine clinical laboratory processes and manufactures' sample-handling instructions.

Authors:  Ibrahim A Hashim; Mishkat Mohamed; Aileen Cox; Fernabelle Fernandez; Patricia Kutscher
Journal:  Pract Lab Med       Date:  2018-10-24

Review 6.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673

7.  The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score.

Authors:  Patrick Chaftari; Anne-Marie Chaftari; Ray Hachem; Sai-Ching J Yeung; Hiba Dagher; Ying Jiang; Alexandre E Malek; Natalie Dailey Garnes; Victor E Mulanovich; Issam Raad
Journal:  Cancer Med       Date:  2021-11-01       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.